BioSpace News Archive

Novavax, Inc. (Nasdaq: NVAX), a biotechnology company developing next-generation vaccines for serious infectious diseases, today announced the complete enrollment of PREVENT-19, its pivotal Phase 3 study in the United States and Mexico to evaluate the efficacy, safety and immunogenicity of the company’s COVID-19 vaccine.

Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH) today announced changes to the Company’s Board of Directors

Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced the appointment of Todd E. Shegog to its Board of Directors.

Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced participation in the Cowen 41 st Annual Health Care Conference, a virtual event taking place March 1-4, 2021.

Cue Biopharma, Inc. (NASDAQ: CUE), a clinical-stage biopharmaceutical company engineering a novel class of injectable biologics designed to selectively engage and modulate targeted T cells within the patient’s body, announced today that Anish Suri, Ph.D., president and chief scientific officer of Cue Biopharma, will deliver an oral presentation and participate in a panel discussion at the 7 th Annual Immuno-Oncology 360° Conference on February 25, 2021

Catalyst Pharmaceuticals, Inc. (Catalyst) (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on developing and commercializing innovative therapies for people with rare debilitating, chronic neuromuscular and neurological diseases, today announced its support for Rare Disease Day 2021.

Cartesian Therapeutics, a fully integrated, clinical-stage biopharmaceutical company pioneering mRNA-engineered cell therapy in and beyond oncology, today announced that it has initiated a Phase 2a clinical trial of its mRNA chimeric antigen receptor (CAR) T-cell therapy, Descartes-11,

Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., one of the world’s leading companies in the diagnostic imaging business, announced today that its ultrasound enhancing agent (UEA) LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use, received FDA approval on a new 20-vial pack configuration

The Microbiome Therapeutics Innovation Group (MTIG) announced today the addition of Microba Life Sciences to its coalition of companies leading the research and development of FDA-approved microbiome therapeutics and microbiome-based products.

Microbion Corporation of Bozeman, MT, and Microbion Pharma Corp. of Vancouver, BC (“Microbion”) today announced that it has received additional funding from the Cystic Fibrosis Foundation to speed the advancement of inhaled pravibismane for the treatment of cystic fibrosis (CF) related pulmonary infections.